This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Quality of Life  • Neoplasms  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Marie-France Demierre, MD, FRCPC; Amy Tien, MD; Donald Miller, ScD

Arch Dermatol. 2005;141:325-330.

Objective  To measure and evaluate the health-related quality of life (HRQOL) in patients with cutaneous T-cell lymphoma (CTCL), a visible cutaneous malignancy that may have a profound effect on patients’ lives.

Design  Monocenter, cross-sectional study.

Setting  The Skin Oncology Program, Department of Dermatology, and the Photopheresis Unit of Boston Medical Center.

Patients  A total of 22 adult patients with confirmed CTCL.

Main Outcome Measures  (1) Evaluation of general oncologic and skin disease–specific HRQOL using, respectively, the Functional Assessment of Cancer Therapy–General (FACT-G) and Skindex-29 profiles; (2) assessment of HRQOL association with disease stage (early stage, IA-IIA; late stage, IIB-IVB).

Results  Patients with more advanced CTCL stages reported more effects on general health (FACT-G), particularly in the physical, emotional, and functional domains (P<.05). Patients with early-stage CTCL reported better skin-specific HRQOL overall (Skindex-29; P = .002) and for each specific domain than did patients with late-stage disease. The Skindex-29 scales had high internal consistency, and the confirmatory factor structure was similar to that of previous studies.

Conclusions  The HRQOL of patients with CTCL can be evaluated using the Skindex-29 and FACT-G instruments. Patients with more advanced stages of CTCL had lower HRQOL scores.

Author Affiliations: Department of Dermatology, Boston University School of Medicine (Drs Demierre and Miller); Department of Medicine, Boston University Medical Center (Dr Tien); and Boston University School of Public Health (Dr Miller), Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy
Christiane Querfeld, Steven T. Rosen, Timothy M. Kuzel, Katharine A. Kirby, Henry H. Roenigk, Jr, Bettina M. Prinz, and Joan Guitart
Arch Dermatol. 2005;141(3):305-311.
ABSTRACT | FULL TEXT  

Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma and Neutrophilic Dermatosis
Nathalie Franck, Agnes Carlotti, Isabelle Gorin, Marc Buffet, Christine Mateus, Nicolas Dupin, and for the French Study Group on Cutaneous Lymphomas
Arch Dermatol. 2005;141(3):353-356.
ABSTRACT | FULL TEXT  

Monoclonal T-Cell Dyscrasia of Undetermined Significance Associated With Recalcitrant Erythroderma
Robert Gniadecki and Ansgar Lukowsky
Arch Dermatol. 2005;141(3):361-367.
ABSTRACT | FULL TEXT  

Dyscrasias With "Undetermined Significance"
Günter Burg, Reinhard Dummer, and Werner Kempf
Arch Dermatol. 2005;141(3):382-384.
EXTRACT | FULL TEXT  

Drug-Induced Eosinophilia and Systemic Symptoms: Hypersensitivity or Peripheral T-Cell Lymphoma?
Nicolas Schleinitz, Véronique Veit, Diane Coso, Thérèse Aurran, Phillippe Berbis, and Jean-Robert Harle
Arch Dermatol. 2005;141(3):395-396.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Measuring HRQOL in Patients With Cutaneous T-Cell Lymphoma Undergoing Therapy With Oral Bexarotene and Extracorporeal Photopheresis
Demierre et al.
Arch Dermatol 2007;143:659-661.
FULL TEXT  

Palliative Care in Patients With Primary Cutaneous Lymphoma: Symptom Burden and Characteristics of Hospital Palliative Care Team Input
LeBon et al.
Arch Dermatol 2007;143:423-424.
FULL TEXT